<?xml version="1.0" encoding="UTF-8"?>
<p id="Par22">Tocilizumab, a drug approved by FDA for rheumatoid arthritis and cytokine release syndrome (CRS), seems to be helpful in patients infected with COVID-19. These patients can develop uncontrolled immune response leading to serious life-threatening damage to lung tissue. Tocilizumab is not active against the virus, however, inhibiting the interleukin-6 receptor it could decrease theÂ systemic inflammation (cytokine release storm) and consequently improve the prognosis [
 <xref ref-type="bibr" rid="CR29">29</xref>, 
 <xref ref-type="bibr" rid="CR30">30</xref>].
</p>
